Application of lactobacillus mucilaginosus IOB802 in regulation of generation of valeric acid

Abstract

The invention provides application of lactobacillus mucus IOB802 to regulation of generation of valeric acid, and belongs to the technical field of microorganisms, and the preservation number of the lactobacillus mucus IOB802 is CGMCC (China General Microbiological Culture Collection Center) No.23120. In the in-vivo metabolism process, the fermented lactobacillus mucus IOB802 promotes the increase of the generation of valeric acid, regulates the generation of cell factors, promotes the differentiation and proliferation of immune cells, repairs immune related organ injuries, relieves thymus atrophy and spleen enlargement, repairs liver and small intestine mucosa injuries, and contributes to improving the immunity of the organism.

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and particularly relates to application of fermented mucus lactobacillus IOB802 in regulating valeric acid production. Background Art

[0002] The human immune system is a complex and sophisticated defense network in which immune cells play a key role. Immune cytokines are messenger molecules for interactions between immune cells and are essential for regulating immune responses. Among them, interleukin-10 (IL-10) is an important anti-inflammatory cytokine that plays an important role in maintaining the balance and homeostasis of the immune system.

[0003] Studies have found that valeric acid has a unique function in regulating the immune system. Valeric acid can induce the production of the immune cytokine IL-10. When IL-10 levels increase, a series of physiological effects that are beneficial to enhancing immunity will occur. Specifically, it can significantly increase the activity of lymphocytes. Lymphocytes, as core members of the immune system, include T lymphocytes, B lymphocytes, etc. The increase in their activity means that immune cells can more effectively identify and respond to foreign pathogens, such as viruses and bacteria.

[0004] At the same time, under the action of valeric acid inducing IL-10 production, the proliferation and differentiation of immune cells are also promoted. The proliferation of immune cells can increase the number of immune cells and provide sufficient "troops" for the immune system; while the differentiation of immune cells can make immune cells develop in a more professional and functional direction, such as differentiating initial T cells into effector T cells, so as to perform immune defense tasks more accurately. These processes combined can effectively improve the body's immunity and make the body more resistant to various pathogens.

[0005] In the prior art, there are various methods for regulating immunity, but the way to indirectly improve immunity by regulating valeric acid production has not been fully developed and utilized. Although the role of valeric acid in immune regulation has been recognized, there is currently a lack of an effective means to accurately regulate the level of valeric acid in the body.

[0006] Probiotics can avoid the side effects that may be caused by the use of chemical synthetic drugs, and based on the beneficial effects of probiotics themselves on the intestinal microecology, they help maintain the balance of intestinal flora. Long-term use of probiotics will not cause the body to develop tolerance or dependence like some drugs.

[0007] Therefore, it is urgent to develop a probiotic that can regulate valeric acid production. Summary of the invention

[0008] In view of the technical problems existing in the prior art, the present invention aims to provide an application of fermented mucus Lactobacillus IOB802 in regulating valeric acid production.

[0009] Fermented Lactobacillus mucilaginosus IOB802, classified as Lactobacillus plantarum Limosilactobacillusfermentum , was deposited on August 5, 2021 in the General Microbiology Center of China Microorganism Culture Collection, referred to as CGMCC, with the address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and its deposit number is CGMCC No. 23120.

[0010] One of the purposes of the present invention is to provide an application of fermented Lactobacillus mucilaginosus IOB802 in regulating valeric acid production. The deposit number of fermented Lactobacillus mucilaginosus IOB802 is CGMCC No.23120.

[0011] Preferably, fermentation of Lactobacillus mucilaginosus IOB802 can be used to prepare a medicine for regulating valeric acid production.

[0012] Preferably, the drug for regulating valeric acid production comprises fermented Lactobacillus mucilaginosus IOB802 bacterial powder and / or fermented Lactobacillus mucilaginosus IOB802 postbiotic powder.

[0013] Preferably, the preparation method of fermented Lactobacillus mucilaginosus IOB802 powder and fermented Lactobacillus mucilaginosus IOB802 postbiotic powder comprises: The fermented Lactobacillus mucilaginosus IOB802 in the cryopreservation tube was inoculated into the primary culture medium at a 1% inoculation amount, and was cultured in a sealed environment at 37°C for 22 hours to obtain a seed solution; the seed solution was inoculated into the secondary culture medium at a 1% inoculation amount, and was cultured in a sealed environment at 37°C for 22 hours to obtain a fermented Lactobacillus mucilaginosus IOB802 fermentation solution; The fermented Lactobacillus mucilaginosus IOB802 broth was centrifuged at 5000 rpm for 30 min at 4°C, the supernatant was discarded, the bacterial sludge was pre-frozen at -80°C for 4 h, and then vacuum freeze-dried to obtain the fermented Lactobacillus mucilaginosus IOB802 bacterial powder; The fermented Lactobacillus mucilaginosus IOB802 powder was heat-inactivated at 85° C. for 15 min to obtain the fermented Lactobacillus mucilaginosus IOB802 postbiotic powder.

[0014] Preferably, the primary culture medium and the secondary culture medium are modified MRS liquid culture medium.

[0015] Preferably, the preparation method of the improved MRS liquid culture medium comprises: mixing 20 g of yeast extract powder, 20 g of glucose, 5 g of sodium acetate, 2 g of triammonium citrate, 801 mL of Tween, 2 g of dipotassium hydrogen phosphate, 0.05 g of manganese sulfate, 0.2 g of magnesium sulfate and 1000 mL of distilled water, pH 7.2-7.4, stirring evenly, and sterilizing at 121° C. and 0.1 MPa for 20 min to obtain the improved MRS liquid culture medium.

[0016] Preferably, the number of viable bacteria in the fermented Lactobacillus mucilaginosus IOB802 powder is 1×10 9 -1×10 11 CFU / g.

[0017] Preferably, fermented Lactobacillus mucilaginosus IOB802 can be used to prepare health products that help enhance immunity.

[0018] Beneficial effects of the present invention: The present invention provides an application of fermented mucus lactobacillus IOB802 in regulating valeric acid production. During the metabolism in the body, the bacteria participates in the metabolic pathway related to valeric acid production through its own enzyme system or metabolites. It can change the chemical composition of the intestinal microenvironment, or directly participate in the metabolism of valeric acid synthesis precursors, thereby promoting the increase of valeric acid production.

[0019] Valeric acid is an important metabolic regulator. When the valeric acid level in the body changes due to the action of fermented Lactobacillus mucilaginosus IOB802, valeric acid can interact with specific receptors on immune cells. This interaction activates the intracellular signal transduction mechanism, further inducing immune cells to synthesize and secrete immune cytokines IL-10 and IL-4. This process involves the initiation and regulation of complex intracellular signaling pathways, which enables immune cells to respond at the gene expression level and produce these cytokines that have an important impact on immune function.

[0020] IL-10 and IL-4 are key immunomodulators that bind to corresponding receptors on the surface of lymphocytes. This binding triggers a series of biochemical changes in lymphocytes, including activation and regulation of key intracellular signaling molecules. For example, they may affect signal transduction pathways in lymphocytes, thereby changing the metabolic state and functional activity of lymphocytes, prompting lymphocytes to change from a relatively static state to a more active state, and enhancing their ability to recognize and respond to foreign antigens.

[0021] Regarding the proliferation of immune cells, IL-10 and IL-4 exert their effects by acting on regulatory mechanisms related to the cell cycle. They can promote the expression of cell cycle proteins and affect the activity of cyclin-dependent kinases, driving immune cells to smoothly pass through various stages of the cell cycle and achieve an increase in number. In terms of immune cell differentiation, IL-10 and IL-4 can regulate the expression and activity of transcription factors related to differentiation, affect the expression levels of Th1 / Th2 cell differentiation-related transcription factors during T lymphocyte differentiation, and guide initial T lymphocytes to differentiate into specific functional subsets, thereby promoting immune cell proliferation and differentiation and improving the body's immunity. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 is the intestinal valeric acid content of mice; Figure 2 is the content of IL-4 in mouse serum; Figure 3 is the content of IL-6 in mouse serum; Figure 4 is the content of IL-10 in mouse serum; Figure 5 is the content of IL-12 in mouse serum; Figure 6 is the content of TNF-α in mouse serum; Figure 7 is the content of IFN-γ in mouse serum; Figure 8 is the transcription level of mouse T-bet transcription factor; Fig. 9 is the transcription level of mouse GATA-3 transcription factor; Fig.10 is the mouse spleen lymphocyte T cell stimulation index; Fig.11 is the mouse spleen lymphocyte B cell stimulation index; Fig.12 is the mouse thymus index; Fig.13 is the mouse spleen index; Fig.14 is the ALT content in mouse serum; Fig.15 is the serum AST content of mice; Fig.16 Mouse liver slices; Fig.17 This is a mouse small intestine tissue section.

[0023] The fermented mucus lactobacillus IOB802 used in the present invention is classified and named as plant lactobacillus Limosilactobacillusfermentum, was deposited on August 5, 2021 in the General Microbiology Center of China Microorganism Culture Collection, referred to as CGMCC, with the address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and its deposit number is CGMCC No. 23120. DETAILED DESCRIPTION

[0024] The invention provides an application of fermented Lactobacillus mucilaginosus IOB802 in regulating the production of valeric acid.

[0025] In a preferred embodiment of the present invention, fermentation of Lactobacillus mucilaginosus IOB802 can be used to prepare medicines for regulating valeric acid production.

[0026] In a preferred embodiment of the present invention, the drug for regulating valeric acid production comprises fermented Lactobacillus mucilaginosus IOB802 bacterial powder and / or fermented Lactobacillus mucilaginosus IOB802 postbiotic powder.

[0027] In a preferred embodiment of the present invention, the preparation method of fermented Lactobacillus mucilaginosus IOB802 bacterial powder and fermented Lactobacillus mucilaginosus IOB802 postbiotic powder comprises: The fermented Lactobacillus mucilaginosus IOB802 in the cryopreservation tube was inoculated into the primary culture medium at a 1% inoculation amount, and was cultured in a sealed environment at 37°C for 22 hours to obtain a seed solution; the seed solution was inoculated into the secondary culture medium at a 1% inoculation amount, and was cultured in a sealed environment at 37°C for 22 hours to obtain a fermented Lactobacillus mucilaginosus IOB802 fermentation solution; The fermented Lactobacillus mucilaginosus IOB802 broth was centrifuged at 5000 rpm for 30 min at 4°C, the supernatant was discarded, the bacterial sludge was pre-frozen at -80°C for 4 h, and then vacuum freeze-dried to obtain the fermented Lactobacillus mucilaginosus IOB802 bacterial powder; The fermented Lactobacillus mucilaginosus IOB802 powder was heat-inactivated at 85° C. for 15 min to obtain the fermented Lactobacillus mucilaginosus IOB802 postbiotic powder.

[0028] In a preferred embodiment of the present invention, both the primary culture medium and the secondary culture medium are modified MRS liquid culture medium.

[0029] In a preferred embodiment of the present invention, the preparation method of the improved MRS liquid culture medium comprises: mixing 20 g of yeast extract powder, 20 g of glucose, 5 g of sodium acetate, 2 g of triammonium citrate, 801 mL of Tween, 2 g of dipotassium hydrogen phosphate, 0.05 g of manganese sulfate, 0.2 g of magnesium sulfate and 1000 mL of distilled water, pH 7.2-7.4, stirring evenly, and sterilizing at 121° C. and 0.1 MPa for 20 min to obtain the improved MRS liquid culture medium.

[0030] In a preferred embodiment of the present invention, the number of viable bacteria of the fermented Lactobacillus mucilaginosus IOB802 powder is 1×109 -1×10 11 CFU / g.

[0031] In a preferred embodiment of the present invention, fermented Lactobacillus mucilaginosus IOB802 can be used to prepare health products that help enhance immunity.

[0032] Example 1 Preparation of fermented Lactobacillus mucilaginosus IOB802 powder and postbiotic powder (1) Preparation of modified MRS liquid culture medium: Mix 20 g of yeast extract powder, 20 g of glucose, 5 g of sodium acetate, 2 g of triammonium citrate, 801 mL of Tween, 2 g of dipotassium hydrogen phosphate, 0.05 g of manganese sulfate, 0.2 g of magnesium sulfate and 1000 mL of distilled water, pH 7.2-7.4, stir evenly, and sterilize at 121°C, 0.1 MPa for 20 min.

[0033] (2) Process flow The fermented mucus Lactobacillus IOB802 in the cryopreserved tube was inoculated into the primary culture medium at a 1% inoculation amount, and was cultured in a closed environment at 37°C for 22 hours to obtain a seed solution. The seed solution was inoculated into the secondary culture medium at a 1% inoculation amount, and was cultured in a closed environment at 37°C for 22 hours to obtain a fermented mucus Lactobacillus IOB802 fermentation liquid. Both the primary culture medium and the secondary culture medium were modified MRS liquid culture medium.

[0034] The fermented Lactobacillus mucilaginosus IOB802 broth was centrifuged at 5000 rpm for 30 min at 4° C., the supernatant was discarded, the bacterial sludge was pre-frozen at -80° C. for 4 h, and then vacuum freeze-dried to obtain the fermented Lactobacillus mucilaginosus IOB802 bacterial powder.

[0035] (3) Activity detection According to the method of GB4789.35-2024 National Food Safety Standard Food Microbiology Test Lactic Acid Bacteria Test, the final test result was 3.55×10 10 CFU / g.

[0036] The fermented Lactobacillus mucilaginosus IOB802 powder was heat-inactivated at 85° C. for 15 min to obtain the fermented Lactobacillus mucilaginosus IOB802 postbiotic powder.

[0037] Example 2 Effects of fermented Lactobacillus mucilaginosus IOB802 on intestinal valeric acid and other short-chain fatty acids Thirty-two 7-week-old SPF BALB / C mice were divided into 4 groups, with 8 mice in each group, namely the normal group, model group, bacterial powder group, and postbiotic group. After a 7-day adaptation period, cyclophosphamide (80 mg / kg) was intraperitoneally injected on the 1st, 2nd, 3rd, 18th, and 22nd days of the experiment to establish an immunosuppressive mouse model. The normal group was given an equal amount of normal saline. From the 4th to the 28th day, the mice were gavaged daily. The fermented Lactobacillus mucosus IOB802 group was gavaged with fermented Lactobacillus mucosus IOB802 bacterial powder (1×10 9 CFU / mL) 0.2mL / day; fermented mucus Lactobacillus IOB802 postbiotic group was intragastrically administered with fermented mucus Lactobacillus IOB802 postbiotic powder (1×10 9 The normal group and the model group were gavaged with an equal amount of saline (0.2 mL) every day.

[0038] On the 28th day, the mice were killed, the cecum was dissected, and the feces of the mice were quickly collected and stored in sterile cryopreservation tubes. 0.1g of feces was taken into a sterile centrifuge tube, 400μL of saturated NaCl solution was added, and 20μL of 10% H2SO4 was used to adjust the pH to about 2.00, vortexed for 2min, fully mixed until there were no particles, and allowed to stand for 20min. 500μL of ether was added, oscillated and mixed, allowed to stand for 10min, and then centrifuged at 13000rpm for 15min; the upper ether phase was taken, 0.20g of anhydrous Na2SO4 was added for drying; after being stored at 4℃ for 10min, centrifuged at 13000rpm for 15min, the upper ether phase was taken and filtered through a 0.22μm organic phase filter, and placed in a -20℃ refrigerator overnight. Gas chromatography was used to analyze the fatty acids in the intestines of each group of mice, with the retention time of chromatographic grade acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid on the gas chromatography column as a reference.

[0039] The content of short-chain fatty acids in the intestinal tract of mice is shown in Table 1. After the intervention of fermented mucus Lactobacillus IOB802, the content of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid and isovaleric acid in the feces of mice in the bacterial powder group and the postbiotic group increased to varying degrees compared with the model group. The effect of the bacterial powder group was better than that of the postbiotic group. Figure 1 As shown in the figure, the valeric acid level of the postbiotic group recovered to 71.31% of that of the normal group, and the valeric acid level of the bacterial powder group was basically the same as that of the normal group. It can be seen that fermented mucus Lactobacillus IOB802 can restore and regulate the production of short-chain fatty acids in the intestine, especially the production of valeric acid.

[0040] Table 1 Short-chain fatty acid content in mouse intestine

[0041] Example 3 Effects of fermented Lactobacillus mucilaginosus IOB802 on serum cytokines Experimental materials: Mouse interleukin-4 (IL-4) ELISA kit, mouse interleukin-6 (IL-6) ELISA kit, mouse interleukin-10 (IL-10) ELISA kit, mouse interleukin-12 (IL-12) ELISA kit, mouse tumor necrosis factor (TNF-α) ELISA kit and mouse interferon-γ (IFN-γ) ELISA kit were all purchased from Nanjing Herborist Biotechnology Co., Ltd.

[0042] The animal experiment design and gavage groups involved in this example are the same as those in Example 2. Blood was collected from the eyeballs of mice and placed in a 2 mL centrifuge tube, cooled on ice for 30 min, and then centrifuged at 3000 rpm for 5 min to collect the upper serum. The contents of IL-4, IL-6, IL-10, IL-12, TNF-α and IFN-γ in mouse serum were detected according to the instructions of the relevant kits. The measurement results are shown in Figure 2 , Figure 3 , Figure 4 , Figure 5 , Figure 6 and Figure 7 As shown in the figure, the levels of various serum cytokines in the mice in the fermented Lactobacillus mucilaginosus IOB802 powder group were significantly improved, among which the anti-inflammatory factors IL-4 and IL-10 had obvious effects, and the content was close to the normal level. The regulatory effect of postbiotics on IL-4 and IL-10 was better than that of other cytokines.

[0043] Example 4 Effects of fermented Lactobacillus mucilaginosus IOB802 on Th cell differentiation T-bet and GATA-3 are the main regulatory factors of Th1 cells and Th2 cells, respectively. T-bet forms a positive feedback on the differentiation of Th cells into Th1 cells by inducing the expression of cytokines. GATA-3 transcription factor can stimulate signal transduction and transcription activators to induce the differentiation of Th cells into Th2 cells.

[0044] The animal experiment design and gavage groups involved in this embodiment are the same as those in Example 2. After RNA was extracted from the spleen tissue of each group of mice, cDNA was synthesized using the HiFi-ScriptcDNAKit reverse transcription kit. The target gene sequence of mouse spleen immune factor was queried in the NCBI database and the corresponding primers were designed. Quantitative PCR (qPCR) was performed using the fluorescent dye SYBR-Green to analyze the transcription level of each transcription factor.

[0045] The transcription levels of mouse T-bet and GATA-3 transcription factors are shown in Figure 8 and Fig. 9The transcription levels of the two transcription factors in the bacterial powder group and the postbiotic group were much higher than those in the model group, and the transcription level in the bacterial powder group was twice that of the model group. After ingestion of fermented mucus Lactobacillus IOB802, the differentiation of Th cells in spleen lymphocytes was significantly promoted, and the immune response was enhanced.

[0046] Example 5 Effects of fermented Lactobacillus mucilaginosus IOB802 on lymphocyte proliferation Concanavalin A (ConA) as a polyclonal stimulator can selectively stimulate T cell proliferation, while lipopolysaccharide (LPS) stimulates B cell proliferation. The proliferation of splenic lymphocytes is reflected by measuring the stimulation index of T lymphocytes and B lymphocytes.

[0047] The animal experiment design and gavage groups involved in this example are the same as those in Example 2. Immediately place the mouse spleen in a pre-cooled PBS solution. Subsequently, while grinding and sieving, rinse the sieve with a PBS solution and collect the rinsing fluid into a 10 mL centrifuge tube. After the rinsing fluid is centrifuged at 1000 rpm for 5 minutes, the supernatant is discarded, and red blood cell lysis solution is added. After mixing evenly, centrifuge again at 1000 rpm for 5 minutes, and the above steps are repeated 3 times. The precipitate is suspended in RPMI-1640 cell culture medium to obtain a spleen cell suspension, and trypan blue staining is performed for counting. After determining that the number of live cells is >95%, the cell concentration is adjusted to 1×10 6 cells / mL.

[0048] T cell stimulation index: ConA storage solution was added to RPMI-1640 cell culture medium to prepare 5μg / mL ConARPMI-1640 cell culture medium. 100μL of spleen lymphocyte suspension was added to a 96-well plate, 100μL RPMI-1640 complete medium was added to the control well, and 100μL RPMI-1640 cell culture medium containing ConA was added to the test well. Three parallels were set up for each well. The cell culture plate was placed in a 37°C, 5% CO2 cell culture incubator for 44 hours, and the supernatant was removed with a pipette. 20μL MTT reagent (5mg / mL) and 180μL RPMI-1640 cell culture medium were added again and cultured for another 4 hours. The supernatant was discarded, 150μL DMSO was added and shaken. Subsequently, the absorbance value of each well at 490nm was detected using an enzyme reader. The absorbance values ​​of the test wells and control wells were calculated according to the following formula: Stimulation index = A test group / A control group B cell stimulation index: LPS storage solution was added to RPMI-1640 cell culture medium to prepare RPMI-1640 cell culture medium containing 10 μg / mL LPS. The subsequent steps are the same as the T cell stimulation index detection method.

[0049] Mouse spleen lymphocyte T cell and B cell stimulation index Fig.10 and Fig.11 As shown in the figure, the stimulation index of the bacterial powder group was higher than that of the normal group, and the B cell stimulation index of the postbiotic group was also close to that of the normal group. This shows that after the intervention of fermented mucus Lactobacillus IOB802, both humoral immunity and cellular immunity were restored.

[0050] Example 6 Effects of fermented Lactobacillus mucilaginosus IOB802 on immune organs Immune organs can be divided into central immune organs and peripheral immune organs. Central immune organs mainly include thymus and bone marrow, and peripheral immune organs mainly include spleen, mucosa, and lymph nodes. The immune organ index can systematically evaluate the functional state of the immune system and the health of immune organs. The animal experimental design and gavage groups involved in this embodiment are the same as those in Example 2.

[0051] The thymus and spleen indexes of mice are shown in Table 2. Fig.12 and Fig.13 As shown in the figure, the thymus index and spleen index of the mice in the model group showed that due to the damage of cyclophosphamide, the mice had thymus atrophy and spleen enlargement. The bacterial powder and postbiotics of fermented mucus Lactobacillus had a significant effect on this.

[0052] Table 2 Thymus and spleen index of mice

[0053] Example 7 Effects of fermented Lactobacillus mucilaginosus IOB802 on liver function The liver can produce proteins that assist immunity under the stimulation of cytokines secreted by immune cells, forming positive feedback of immune response, which is also an important part of immune regulation. The animal experiment design, gavage groups and serum treatment methods involved in this embodiment are the same as those in Example 2. According to the steps provided in the instructions of the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) kits, the ALT and AST levels in mouse serum were detected. In addition, an appropriate amount of mouse liver tissue was taken from the same part for H&E staining, and the tissue morphology was observed under an optical microscope (400×).

[0054] The levels of ALT and AST in mouse serum Fig.14 and Fig.15 As shown in the figure, the ALT and AST levels in the serum of the bacterial powder group and the postbiotic group decreased significantly, and the liver damage caused by cyclophosphamide in mice was significantly repaired.

[0055] Mouse liver slices Fig.16As shown. The liver tissue morphology of mice in the normal group was normal, the hepatic cords were radial and neatly arranged, and the hepatocytes were uniform in size and had clear boundaries; the hepatocytes in the model group were enlarged, the hepatic cords were disordered, and inflammatory cells infiltrated; the degree of hepatocyte damage in the bacterial powder group and the postbiotic group was significantly reduced, and the hepatic cords were arranged more neatly. However, although the degree of cell swelling in the postbiotic group was reduced, the gaps between cells indicated that the hepatocytes still had a certain degree of mild swelling and degeneration, and the degree of recovery was not as good as that in the live bacteria group.

[0056] Example 8 Effects of fermented Lactobacillus mucilaginosus IOB802 on intestinal barrier The small intestinal mucosa is part of the immune barrier and is crucial to nonspecific immunity. The core structural units of the small intestinal mucosal barrier are intestinal villi and crypts. The length of intestinal villi is closely related to the absorption and utilization of nutrients, while crypts are an important indicator of intestinal epithelial cell self-renewal.

[0057] The animal experiment design and gavage groups involved in this example are the same as those in Example 2. An appropriate amount of mouse small intestinal tissue was taken from the same part for H&E staining, and the tissue morphology was observed under an optical microscope (200×).

[0058] Mouse intestinal slices Fig.17 As shown in the figure, the small intestinal crypts of mice in the normal group were deeper, the villi were longer and neatly arranged, and the tissue structure was clear. The small intestinal crypts of mice in the model group were shallower and more exposed to the intestine. The villi were significantly shortened and atrophied, sparsely arranged, and the tissue structure was more chaotic and fuzzy. The crypts and villi morphology of the small intestine of mice in the bacterial powder group and the metabiotic group were more similar to those of the normal group, and the small intestinal barrier was repaired.

Claims

1. An application of fermented Lactobacillus mucilaginosus IOB802 in regulating valeric acid production, characterized in that: The deposit number of the fermented mucus lactobacillus IOB802 is CGMCC No.23120.

2. The use according to claim 1, characterized in that The fermented Lactobacillus mucilaginosus IOB802 is used for preparing medicines for regulating valeric acid production.

3. The use according to claim 2, characterized in that The drug for regulating valeric acid production comprises fermented Lactobacillus mucilaginosus IOB802 bacterial powder and / or fermented Lactobacillus mucilaginosus IOB802 postbiotic powder.

4. The use according to claim 3, characterized in that The preparation method of the fermented Lactobacillus mucilaginosus IOB802 bacterial powder and the fermented Lactobacillus mucilaginosus IOB802 postbiotic powder comprises: The fermented Lactobacillus mucilaginosus IOB802 in the cryopreservation tube was inoculated into the primary culture medium at a 1% inoculation amount, and was cultured in a sealed environment at 37°C for 22 hours to obtain a seed solution; the seed solution was inoculated into the secondary culture medium at a 1% inoculation amount, and was cultured in a sealed environment at 37°C for 22 hours to obtain a fermented Lactobacillus mucilaginosus IOB802 fermentation solution; The fermented Lactobacillus mucilaginosus IOB802 broth was centrifuged at 5000 rpm for 30 min at 4°C, the supernatant was discarded, the bacterial sludge was pre-frozen at -80°C for 4 h, and then vacuum freeze-dried to obtain the fermented Lactobacillus mucilaginosus IOB802 bacterial powder; The fermented Lactobacillus mucilaginosus IOB802 powder was heat-inactivated at 85° C. for 15 min to obtain the fermented Lactobacillus mucilaginosus IOB802 postbiotic powder.

5. The use according to claim 4, characterized in that The primary culture medium and the secondary culture medium are improved MRS liquid culture medium.

6. The use according to claim 5, characterized in that The preparation method of the improved MRS liquid culture medium comprises: mixing 20g of yeast extract powder, 20g of glucose, 5g of sodium acetate, 2g of triammonium citrate, 801mL of Tween, 2g of dipotassium hydrogen phosphate, 0.05g of manganese sulfate, 0.2g of magnesium sulfate and 1000mL of distilled water, adjusting the pH to 7.2-7.4, stirring evenly, and sterilizing at 121°C and 0.1MPa for 20min to obtain the improved MRS liquid culture medium.

7. The use according to claim 3, characterized in that The number of live bacteria in the fermented mucus Lactobacillus IOB802 powder is 1×10 9 -1×10 11 CFU / g.

8. The use according to claim 1, characterized in that The fermented mucus lactobacillus IOB802 is used for preparing health products that help to enhance immunity.

Images